bpc-157 human studies clinical trials safety review Heal or Harm: Body Protective Compound-157 in the Gray Zone bpc-157 human clinical trials evidence

Immunogenicity: No Antibody Formation A critical safety consideration for any peptide therapy is immunogenicity, the potential to trigger immune system responses that could lead to allergic reactions, reduced efficacy through antibody neutralization, or autoimmune complications

Usually bad in the morning and late afternoon

Determining the frequency of your shots depends on several factors, such as the severity of your B-12 deficiency and its cause

Low levels of B12 may include fatigue, weakness, pale skin, neurological symptoms, mood changes, or gastrointestinal issues

specific formulations vary by pharmacy and prescriber order

Big Pharma has lost trust due to overcharging for drugs and overmarking products leading to harm, like Vioxx 20 years ago